Allarity Therapeutics (ALLR) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Vyome (HIND) over the past year, losing 42.2% versus a loss of 65.4%. Allarity Therapeutics is the larger company by market cap ($15.6 million vs $14.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | HIND |
|---|---|---|
| Share price | $0.9819 | $2.03 |
| Market cap | $15.62M | $14.25M |
| 1-day change | -0.21% | -0.49% |
| YTD return | -9.08% | -40.99% |
| 1-year return | -42.24% | -65.42% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 1.14 |
| EPS (TTM) | $-0.79 | $1.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $6.56 |
| 52-week low | $0.769 | $1.75 |
| Distance from 52-week high | -46.64% | -69.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1020.28% | +334.98% |
| Average volume | 90.75K | 13.32K |
| Shares outstanding | 15.91M | 7.02M |
| Employees | 7 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed HIND by 23.2 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ALLR vs HIND FAQ
Which is bigger, Allarity Therapeutics or Vyome?
Allarity Therapeutics (ALLR) is larger, with a market capitalization of $15.62M compared with $14.25M for Vyome (HIND).
Which stock has performed better over the past year, ALLR or HIND?
ALLR returned -42.24% over the past 12 months, compared with -65.42% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.